Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05607342 · ClinicalTrials.gov registry record · Early Phase 1
Pilot of Osanetant to Reduce Testosterone in Men With Adenocarcinoma of the Prostate
A Early Phase 1 study, sponsored by University of Kansas Medical Center.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 1
- Enrollment target
NCT05607342: Clinical Trial Early Phase 1 study, sponsored by University of Kansas Medical Center.
NCT05607342 is a Early Phase 1 study that was terminated before completion, run by University of Kansas Medical Center. The registered enrollment target is 1 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05607342, a Early Phase 1 study, was terminated before completion, sponsored by University of Kansas Medical Center.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
To evaluate the effect of Osanetant on testosterone levels in men with prostate cancer within 28 days of therapy.
Primary Outcome
We will test the ability of Osanetant to suppress testosterone production. A single arm pilot study of Osanetant at 200mg twice daily will be performed. Testosterone levels at baseline will be compared to levels at day 2, 3, 7 ,14, and 28 days of therapy. The overall effect of Osanetant on testosterone levels and the proportion of men achieving castrate levels of testosterone (\<50ng/ml) will be assessed. Additionally, the reversibility of this effect will be assessed by evaluating the testoster
Interventions
- DRUG Osanetant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2023-01-03 |
| Est. Completion | 2023-11-06 |
| Phase | Early Phase 1 |
Why NCT05607342 stopped before completion
NCT05607342 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which Osanetant is the first listed.
NCT05607342 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05607342 about?
NCT05607342 is a clinical study titled "Pilot of Osanetant to Reduce Testosterone in Men With Adenocarcinoma of the Prostate". To evaluate the effect of Osanetant on testosterone levels in men with prostate cancer within 28 days of therapy.
What is the current status of trial NCT05607342?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 1 participants. The study started on 2023-01-03. Estimated completion is 2023-11-06.
What interventions are being tested in trial NCT05607342?
The interventions under investigation include: Osanetant (DRUG).
Who is sponsoring clinical trial NCT05607342?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05607342's enrollment target sits among peer trials
1 1985th of 2000 the lowest of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI